Quarterly ResultMay 7, 2026, 04:41 PM
Aclaris Therapeutics Q1 Net Loss $(19.8)M; Raises $57.9M via Equity
AI Summary
Aclaris Therapeutics reported an increased net loss of $(19.8) million for the first quarter of 2026, compared to $(15.1) million in the prior year, primarily due to higher research and development expenses. The company significantly strengthened its financial position by raising $57.9 million through an at-the-market common stock offering. As of March 31, 2026, Aclaris held $190.8 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations for over 12 months.
Key Highlights
- Net loss increased to $(19.8) million in Q1 2026 from $(15.1) million in Q1 2025.
- Total revenue rose to $2.0 million in Q1 2026 from $1.5 million in Q1 2025.
- Research and development expenses increased to $15.7 million in Q1 2026 from $11.6 million in Q1 2025.
- Raised $57.9 million net proceeds from the issuance of 18.4 million common shares via an at-the-market facility in March 2026.
- Cash, cash equivalents, and marketable securities totaled $190.8 million as of March 31, 2026.
- Net cash used in operating activities was $(18.1) million in Q1 2026, up from $(13.1) million in Q1 2025.